Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Celldex Therapeutics (CLDX) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Celldex Therapeutics is a member of the Medical sector. This group includes 833 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CLDX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CLDX's full-year earnings has moved 34.14% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that CLDX has returned about 58.41% since the start of the calendar year. At the same time, Medical stocks have gained an average of 10.46%. As we can see, Celldex Therapeutics is performing better than its sector in the calendar year.
Looking more specifically, CLDX belongs to the Medical - Biomedical and Genetics industry, a group that includes 344 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, this group has gained an average of 15.33% so far this year, meaning that CLDX is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on CLDX as it attempts to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celldex Therapeutics, Inc. (CLDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research